Upcoming Login Downtime
We're updating the Biocentury.com platform login experience to make access more secure and reliable. As part of this update, logins will be temporarily unavailable on Sunday, March 16, from 4:00AM to 4:00PM GMT. We recognize the inconvenience and appreciate your understanding. Please check back after the maintenance period.
For updates, questions, or issues, please call us at +1 650-552-4224 or email us at support@biocentury.com.
- Company Profiles
- Target Profiles
- Product Profiles
Explore BCIQ profiles by entering a company name.
Nanjing Bioheng Biotech Co. Ltd.
BioCentury | Oct 19, 2021
Management Tracks
Carl June joins Bioheng’s SAB
Plus: Myriad, Kura, Ideaya, IASO, OncoCyte and more
BioCentury | Apr 2, 2021
Product Development
Chinese biotechs look to next-generation CAR T technologies to solve market challenges
Chinese CAR T cell companies are mapping out solutions to their cost problem
BioCentury | Nov 14, 2020
Product Development
ASH 2020 snapshot: efficacy data in hot emerging areas
A roundup of clinical trial readouts for CD47 blockers, allogeneic CAR T cells and sickle cell disease
BioCentury | Nov 12, 2020
Product Development
Lining up allogeneic CAR Ts at ASH: Data Byte
Promising efficacy data from China’s Bioheng are among the allogeneic CAR T cell updates at ASH this year. The past year has seen a growing number of clinical readouts for off-the-shelf
Items per page:
1 - 7 of 7